Mauri‐Obradors et al., 2018 - Google Patents
Benefits of non‐surgical periodontal treatment in patients with type 2 diabetes mellitus and chronic periodontitis: A randomized controlled trialMauri‐Obradors et al., 2018
View PDF- Document ID
- 6837242091356194704
- Author
- Mauri‐Obradors E
- Merlos A
- Estrugo‐Devesa A
- Jané‐Salas E
- López‐López J
- Viñas M
- Publication year
- Publication venue
- Journal of clinical periodontology
External Links
Snippet
Background Periodontitis and diabetes are highly prevalent conditions whose association has long been recognized. Objective To evaluate the effect of non‐surgical periodontal treatment on serum HbA1c (haemoglobin A1c or glycated haemoglobin) levels in patients …
- 230000003239 periodontal 0 title abstract description 47
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mauri‐Obradors et al. | Benefits of non‐surgical periodontal treatment in patients with type 2 diabetes mellitus and chronic periodontitis: A randomized controlled trial | |
Teles et al. | Impact of systemic factors in shaping the periodontal microbiome | |
Invernici et al. | Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: a randomized clinical trial | |
Al-Kamel et al. | Subgingival microbiome of experimental gingivitis: shifts associated with the use of chlorhexidine and N-acetyl cysteine mouthwashes | |
Cameron et al. | The human salivary microbiome exhibits temporal stability in bacterial diversity | |
Pushalkar et al. | Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw | |
Miranda et al. | Metronidazole and amoxicillin as adjuncts to scaling and root planing for the treatment of type 2 diabetic subjects with periodontitis: 1‐year outcomes of a randomized placebo‐controlled clinical trial | |
Meurman et al. | Oral health, atherosclerosis, and cardiovascular disease | |
Hajishengallis | The inflammophilic character of the periodontitis‐associated microbiota | |
Koromantzos et al. | A randomized, controlled trial on the effect of non‐surgical periodontal therapy in patients with type 2 diabetes. Part I: effect on periodontal status and glycaemic control | |
Nibali et al. | Gene polymorphisms and the prevalence of key periodontal pathogens | |
Guentsch et al. | Moxifloxacin as an adjunctive antibiotic in the treatment of severe chronic periodontitis | |
Wang et al. | Analysis of oral microbial community and Th17‐associated cytokines in saliva of patients with oral lichen planus | |
Abusleme et al. | Human defects in STAT3 promote oral mucosal fungal and bacterial dysbiosis | |
George et al. | Oral microbiota species in acute apical endodontic abscesses | |
Baek et al. | Association of the invasion ability of Porphyromonas gingivalis with the severity of periodontitis | |
Vardar‐Sengul et al. | Human β defensin‐1 and‐2 expression in the gingiva of patients with specific periodontal diseases | |
Lu et al. | Microbiome in maintained periodontitis and its shift over a single maintenance interval of 3 months | |
Nadkarni et al. | Pattern of distribution of Prevotella species/phylotypes associated with healthy gingiva and periodontal disease | |
Santos et al. | Partial‐and full‐mouth scaling and root planing in type 2 diabetic subjects: a 12‐mo follow‐up of clinical parameters and levels of cytokines and osteoclastogenesis‐related factors | |
Al‐hebshi et al. | Quantitative analysis of classical and new putative periodontal pathogens in subgingival biofilm: a case–control study | |
Joaquim et al. | The combined and individual impact of diabetes and smoking on key subgingival periodontal pathogens in patients with chronic periodontitis | |
Sembler-Møller et al. | Next-generation sequencing of whole saliva from patients with primary Sjögren’s syndrome and non-Sjögren’s sicca reveals comparable salivary microbiota | |
Wang et al. | Relationship between expression of human gingival beta‐defensins and levels of periodontopathogens in subgingival plaque | |
Kinane et al. | Experimental gingivitis, bacteremia and systemic biomarkers: a randomized clinical trial |